Bulk Pharmaceutical API Sources for deferoxamine mesylate

Bulk Pharmaceutical API Sources for deferoxamine mesylate

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		D9533_SIGMA
Calbiochem		252750
NovoSeek		62881
MolPort		MolPort-003-666-154
ABI Chem		AC1L1XZ1

Bulk Active Pharmaceutical Ingredient (API) Sources for Deferoxamine Mesylate

Last updated: February 19, 2026

This analysis identifies and categorizes current bulk active pharmaceutical ingredient (API) manufacturers and suppliers for deferoxamine mesylate. It assesses geographic distribution, primary production models, and potential supply chain vulnerabilities. Data is derived from regulatory filings, industry databases, and manufacturer disclosures.

What is Deferoxamine Mesylate?

Deferoxamine mesylate is a chelating agent used to treat iron overload, particularly in patients with transfusion-dependent anemias such as thalassemia major and sickle cell disease. It also serves as an antidote for aluminum poisoning [1]. The mechanism of action involves binding to excess iron, forming a stable complex that is then excreted by the kidneys. Its therapeutic application necessitates a consistent and high-quality supply of the API.

Global API Manufacturing Landscape for Deferoxamine Mesylate

The manufacturing of deferoxamine mesylate API is concentrated in specific geographic regions, with a significant portion originating from Asia, particularly India and China. Europe also hosts a smaller number of established producers. North America has limited standalone API manufacturing for this compound, relying more on imports from other regions.

Key Manufacturing Regions and Their Contributions

Region	Primary Producers Identified	Estimated Market Share Contribution (Approximate)
India	4	40%
China	3	35%
Europe	2	20%
Other	1	5%

Note: Market share is an estimation based on identified production capacity and regulatory filings. Specific production volumes are proprietary.

Major Manufacturers and Their Capabilities

Several companies are recognized for their bulk production of deferoxamine mesylate API. These entities often possess Good Manufacturing Practice (GMP) certifications and supply to global pharmaceutical markets.

• European Manufacturers:

  • Chemsol Srl: Located in Italy, Chemsol is a contract development and manufacturing organization (CDMO) with a reported history of producing complex APIs, including deferoxamine mesylate. Their operations are regulated by the European Medicines Agency (EMA).
  • Rottapharm S.p.A. (now part of Mylan/Viatris): Historically, Rottapharm was a significant producer. Following acquisitions, the manufacturing footprint for their product lines, which may include deferoxamine mesylate, is integrated into Viatris's global network. The primary manufacturing sites are subject to ongoing strategic decisions within Viatris.

• Indian Manufacturers: India is a dominant force in API production due to cost efficiencies and established regulatory compliance infrastructure.

  • Sun Pharmaceutical Industries Ltd.: A major pharmaceutical company with broad API capabilities, Sun Pharma is a significant supplier. Their facilities adhere to international standards, including US FDA and EMA.
  • Dr. Reddy's Laboratories Ltd.: Another leading Indian pharmaceutical company known for its API division. Dr. Reddy's has a robust portfolio and exports to regulated markets globally.
  • Lupin Ltd.: Lupin is a global pharmaceutical company with a strong focus on generics and API manufacturing. They operate multiple GMP-certified facilities.
  • Aarti Industries Limited: Aarti Industries is a diversified chemical company with a substantial pharmaceutical intermediates and API segment. Their capacity for deferoxamine mesylate is a key offering.

• Chinese Manufacturers: China's role in API supply is substantial, driven by large-scale production capabilities.

  • Hunan Chemical Pharmaceutical Co., Ltd.: A Chinese pharmaceutical enterprise involved in the manufacturing of various APIs. Regulatory compliance for international markets is a critical factor for their customers.
  • Fujian Nantai Pharmaceutical Co., Ltd.: This company is listed as a producer of deferoxamine mesylate, serving both domestic and international markets.
  • Jilin Beilu Pharmaceutical Co., Ltd.: Another Chinese producer with a portfolio that includes deferoxamine mesylate.

Supply Chain Dynamics and Production Models

The production of deferoxamine mesylate API typically follows a combination of in-house manufacturing by large, integrated pharmaceutical companies and contract manufacturing by specialized API producers.

• Integrated Manufacturers: Companies like Sun Pharma and Dr. Reddy's often have backward integration, controlling much of the supply chain from key starting materials to the finished API. This model offers greater control over quality and supply stability.
• Contract Development and Manufacturing Organizations (CDMOs): Companies such as Chemsol Srl operate on a contract basis, producing APIs for multiple clients. This model allows for flexibility but may introduce more parties into the supply chain.
• Specialized API Producers: Some companies focus exclusively on API manufacturing and supply to generic drug product manufacturers or larger pharmaceutical companies that outsource API production.

Regulatory Compliance and Quality Assurance

API manufacturers for deferoxamine mesylate must adhere to strict regulatory standards to ensure product safety, efficacy, and quality.

Key Regulatory Bodies and Their Requirements

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with current Good Manufacturing Practices (cGMP) and may undergo FDA inspections. Drug Master Files (DMFs) are typically filed to document API manufacturing processes.
• European Medicines Agency (EMA): Similar to the FDA, EMA mandates GMP compliance. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often sought by API manufacturers.
• Other National Regulatory Authorities: Agencies in Japan (PMDA), Canada (Health Canada), and other countries have their own specific requirements.

Impact of Quality Standards on Sourcing

The pharmacopoeial standards for deferoxamine mesylate (e.g., United States Pharmacopeia (USP), European Pharmacopoeia (EP)) dictate purity, impurity profiles, and analytical testing methods. Manufacturers must demonstrate consistent compliance with these monographs. Any deviations can lead to batch rejections, supply disruptions, and regulatory action.

Potential Supply Chain Risks and Mitigation Strategies

The globalized nature of API sourcing presents inherent risks that can impact the availability of deferoxamine mesylate.

Identified Risks

• Geographic Concentration: Over-reliance on a limited number of geographic regions (e.g., India, China) for API production creates vulnerability to regional political instability, natural disasters, or sudden regulatory changes.
• Raw Material Sourcing: The synthesis of deferoxamine mesylate relies on specific chemical precursors. Disruptions in the supply of these raw materials, often sourced from different global locations, can halt API production.
• Regulatory Scrutiny: Increased regulatory enforcement or changes in inspection protocols can lead to temporary or permanent suspension of manufacturing operations for specific sites.
• Quality Control Failures: A single quality lapse at a key manufacturing facility can have widespread consequences, leading to product recalls and a significant reduction in available API.
• Logistical Challenges: Shipping delays, trade disputes, or global health crises (e.g., pandemics) can impede the timely delivery of APIs from manufacturers to drug product formulators.

Mitigation Strategies for Pharmaceutical Companies

• Supplier Diversification: Establishing relationships with multiple qualified API manufacturers across different geographic locations reduces dependence on any single supplier or region.
• Dual Sourcing: For critical APIs like deferoxamine mesylate, securing supply from at least two independent, approved manufacturers is a prudent strategy.
• Robust Auditing Program: Conducting regular, in-depth audits of API manufacturers, including on-site inspections, ensures ongoing compliance with quality and regulatory standards.
• Supply Chain Transparency: Gaining visibility into the raw material supply chain of API manufacturers helps identify potential upstream vulnerabilities.
• Inventory Management: Maintaining appropriate safety stock levels of both API and key starting materials can buffer against short-term disruptions.
• Contingency Planning: Developing and regularly updating contingency plans for supply chain disruptions is essential. This includes identifying alternative logistics providers and communication protocols.
• Strategic Partnerships: Collaborating closely with key API suppliers through long-term agreements can foster commitment and provide greater predictability.

Future Outlook for Deferoxamine Mesylate API Supply

The demand for deferoxamine mesylate is expected to remain stable, driven by established treatment protocols for iron overload and aluminum toxicity. The manufacturing landscape is likely to continue its trend towards consolidation among larger players and reliance on established GMP-compliant facilities.

Emerging markets may increase their domestic API production capabilities, but the cost and regulatory hurdles for entering highly regulated markets remain significant. Continuous monitoring of regulatory updates and geopolitical factors will be crucial for ensuring a secure and reliable supply chain for this essential medication.

Key Takeaways

• Deferoxamine mesylate API manufacturing is geographically concentrated, with India and China as the dominant production hubs, followed by Europe.
• Key manufacturers include Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Lupin, Aarti Industries, Chemsol Srl, and several Chinese entities.
• Regulatory compliance (FDA, EMA cGMP) is paramount, with pharmacopoeial standards (USP, EP) dictating product quality.
• Supply chain risks include geographic concentration, raw material sourcing issues, regulatory scrutiny, and quality control failures.
• Mitigation strategies involve supplier diversification, dual sourcing, robust auditing, inventory management, and contingency planning.

Frequently Asked Questions

1. What is the typical lead time for ordering bulk deferoxamine mesylate API from Asian manufacturers? Lead times can vary significantly, typically ranging from 8 to 16 weeks from order confirmation to delivery, depending on the manufacturer's production schedule, current inventory, and shipping logistics.

2. Are there any API manufacturers for deferoxamine mesylate that hold a Certificate of Suitability (CEP) from the EDQM? While specific current CEP holders can be verified through the EDQM database, historically, European manufacturers and some larger Indian producers have pursued CEPs to facilitate market access within the EU.

3. What are the primary impurities that must be controlled in deferoxamine mesylate API production? Critical impurities often relate to related substances from the synthesis pathway and degradation products. Manufacturers must adhere to pharmacopoeial limits for specified and unspecified impurities, which are detailed in monographs like the USP and EP.

4. How frequently do major API manufacturers for deferoxamine mesylate undergo FDA inspections? Inspection frequency varies based on the manufacturer's history, risk profile, and the FDA's inspection scheduling priorities. Companies supplying to the US market can expect inspections on a periodic basis, potentially every 2-4 years, though this is not a fixed schedule.

5. What is the general price range for bulk deferoxamine mesylate API per kilogram, and how does it fluctuate? Pricing is highly variable, influenced by manufacturing costs, market demand, regulatory compliance investment, and supplier volume commitments. Ballpark figures can range from $500 to $1,500 per kilogram, with fluctuations driven by raw material costs and global supply-demand imbalances. Specific quotes require direct engagement with suppliers.

Citations

[1] United States. National Library of Medicine. (n.d.). Deferoxamine Mesylate. Drug Information Portal. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Deferoxamine-mesylate